Debevoise & Plimpton LLP advised Lannett Company, Inc. on its $585 million comprehensive refinancing, comprised of the issuance of $350 million aggregate principal amount of 7.75% senior secured notes due 2026, an extension and increase of its $45 million asset-based revolving credit facility and the incurrence of $190 million of second lien senior secured loans, together with the issuance of warrants to second lien lenders. For more information, please see the company’s
press release.
Lannett develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.